Some thoughts on surgical adjuvant studies in lung cancer.
D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011379:Prognosis; D013997:Time Factors
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004338:Drug Combinations; D009607:Nitrosourea Compounds; D003520:Cyclophosphamide; D006918:Hydroxyurea